Current limitations include therapeutic safety concerns, such as pruritus and adverse lipid changes with FXR agonists like obeticholic acid, and uncertainties in long-term efficacy for emerging drugs like FGF21 analogs, which show short-term fibrosis reductions but require extended trials to confirm HCC prevention. Here, FGF21 is linked to hepatocellular carcinoma.